Abstract
Objectives: To study the effect of antiplatelet agents on preventing arteriovenous (AV) fistulae thrombosis in hemodialysis (HD) patients after surgical thrombectomy (ST) for acute AV fistulae occlusion. Whether post-operative antiplatelet drugs have similar effects on the patency of AV fistula after surgical thrombectomy in patients with end-stage renal disease who undergo HD has not been investigated.
Design, Materials and Methods: We employed the Taiwan National Health Insurance Research Database (NHIRD) from 1999 to 2010 to assess the recurrent occlusion requiring ST and longevity of AV fistula after ST in 1049 patients on regular HD, with or without antiplatelet drugs.
Results: From the propensity-score (PS)-matched NHIRD, Multivariate Cox model demonstrated that concomitant antiplatelet medication in the HD patients who received the first ST significantly reduced the duration of recurrent ST (adjusted hazard ratio (HR) 1.69; 95% confidence interval (CI) 1.22-2.35, p=0.002) and the longevity of the fistula (adjusted HR 1.79; 95% CI 1.31-2.46, p<0.001).
Conclusion: Treatment with antiplatelet drugs in HD patients did not prevent recurrent thrombosis requiring further ST, but significantly jeopardized the longevity of AV fistula after ST.
Keywords: Antiplatelet drugs, arteriovenous fistula, thrombectomy, vascular patency.
Current Vascular Pharmacology
Title:Effects of Antiplatelet Medication on Arteriovenous Fistula Patency After Surgical Thrombectomy
Volume: 14 Issue: 4
Author(s): Chi-Hsiao Yeh, Ting-Shuo Huang, Yao-Chang Wang, Pin-Fu Huang, Tzu-Yen Huang, Tzu-Ping Chen, Shun-Ying Yin and Yu-Wei Yu
Affiliation:
Keywords: Antiplatelet drugs, arteriovenous fistula, thrombectomy, vascular patency.
Abstract: Objectives: To study the effect of antiplatelet agents on preventing arteriovenous (AV) fistulae thrombosis in hemodialysis (HD) patients after surgical thrombectomy (ST) for acute AV fistulae occlusion. Whether post-operative antiplatelet drugs have similar effects on the patency of AV fistula after surgical thrombectomy in patients with end-stage renal disease who undergo HD has not been investigated.
Design, Materials and Methods: We employed the Taiwan National Health Insurance Research Database (NHIRD) from 1999 to 2010 to assess the recurrent occlusion requiring ST and longevity of AV fistula after ST in 1049 patients on regular HD, with or without antiplatelet drugs.
Results: From the propensity-score (PS)-matched NHIRD, Multivariate Cox model demonstrated that concomitant antiplatelet medication in the HD patients who received the first ST significantly reduced the duration of recurrent ST (adjusted hazard ratio (HR) 1.69; 95% confidence interval (CI) 1.22-2.35, p=0.002) and the longevity of the fistula (adjusted HR 1.79; 95% CI 1.31-2.46, p<0.001).
Conclusion: Treatment with antiplatelet drugs in HD patients did not prevent recurrent thrombosis requiring further ST, but significantly jeopardized the longevity of AV fistula after ST.
Export Options
About this article
Cite this article as:
Yeh Chi-Hsiao, Huang Ting-Shuo, Wang Yao-Chang, Huang Pin-Fu, Huang Tzu-Yen, Chen Tzu-Ping, Yin Shun-Ying and Yu Yu-Wei, Effects of Antiplatelet Medication on Arteriovenous Fistula Patency After Surgical Thrombectomy, Current Vascular Pharmacology 2016; 14 (4) . https://dx.doi.org/10.2174/1570161114666160229115844
DOI https://dx.doi.org/10.2174/1570161114666160229115844 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Attenuating Diabetes: What Really Works?
Current Diabetes Reviews The Role of Neuroendocrine Cells in Prostate Cancer: A Comprehensive Review of Current Literature and Subsequent Rationale to Broaden and Integrate Current Treatment Modalities
Current Medicinal Chemistry Atherogenesis in Renal Patients: A Model of Vascular Disease?
Current Vascular Pharmacology The Serpin Solution; Targeting Thrombotic and Thrombolytic Serine Proteases in Inflammation
Cardiovascular & Hematological Disorders-Drug Targets Recent Advances on the Roles of NO in Cancer and Chronic Inflammatory Disorders
Current Medicinal Chemistry Mastering the Treatment of Diabetes Mellitus Type 1 in Childhood and Adolescence
Current Pediatric Reviews The Two fACEs of the Tissue Renin-Angiotensin Systems: Implication in Cardiovascular Diseases
Current Pharmaceutical Design Matrix Metalloproteinases: A Therapeutic Target in Cardiovascular Disease
Current Pharmaceutical Design Alveolar Capillary Dysplasia: A Lethal Developmental Lung Malformation
Current Respiratory Medicine Reviews Coagulation Factor XIIIA (F13A1): Novel Perspectives in Treatment and Pharmacogenetics
Current Pharmaceutical Design Subject Index Volume 2
Current Pediatric Reviews Fibrosis in the Anterior Segments of the Eye
Endocrine, Metabolic & Immune Disorders - Drug Targets Drug-Induced Thromboembolic Events in Patients with Malignancy
Cardiovascular & Hematological Disorders-Drug Targets Non-Surgical Treatment Options for Symptomatic Uterine Leiomyomas
Current Women`s Health Reviews The Lung Disease of Rheumatoid Arthritis
Current Respiratory Medicine Reviews Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases
Mini-Reviews in Medicinal Chemistry Sex Steroid Hormones, Cardiovascular Diseases and The Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Can Breast Cancer Stem Cells Evade the Immune System?
Current Medicinal Chemistry Buccal Delivery of Methimazole as an Alternative Means for Improvement of Drug Bioavailability: Permeation Studies and Matrix System Design
Current Pharmaceutical Design Recent Clinical Trials of Pharmacologic Cardiovascular Interventions in Patients with Chronic Kidney Disease
Reviews on Recent Clinical Trials